Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Science (New York, N.Y.)|October 7, 2016
The linker histone H1.0 generates epigenetic and functional intratumor heterogeneityCristina Morales Torres, Alva Biran, Matthew J Burney, et al.
The World Allergy Organization Journal|March 23, 2026
Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosisThanai Pongdee, Mariana Castells, Cem Akin, et al.
Nature Communications|April 15, 2020
Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axisCristina Morales Torres, Mary Y Wu, Sebastijan Hobor, et al.
Future Oncology (London, England)|February 28, 2025
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastasesMaximilian Marhold, Marta Vaz Batista, Isabel Blancas, et al.
The Journal of Biological Chemistry|May 16, 2026
Titin cleavage in living cardiomyocytes induces sarcomere disassembly but does not trigger cell proliferationMaria Rosaria Pricolo, Miguel A López-Unzu, Natalia Vicente, et al.
Allergy|May 19, 2026
The REMA Score Revisited: An Optimized Algorithm for Early Prediction of Clonal Mast Cell DiseaseIrina Sucre-Adrianza, Horacio Caligaris, Cristina Morales-Cabeza, et al.
Frontiers in Immunology|December 21, 2016
KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid TumorsCristina Morales-Estevez, Juan De la Haba-Rodriguez, Barbara Manzanares-Martin, et al.
Oncogene|March 20, 2021
ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancerThaidy Moreno, Beatriz Monterde, Laura González-Silva, et al.
Blood|August 14, 2025
Improved diagnostic screening and classification of clonal mast cell diseases by ultrasensitive KIT p.D816V detectionPaula Navarro-Navarro, María González-Tablas, Alba Pérez-Pons, et al.
Frontiers in Oncology|November 22, 2019
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World DataTamara Díaz-Redondo, Rocio Lavado-Valenzuela, Begoña Jimenez, et al.
Pageof 8